Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.38 |
| ▸ | HSP90AB1 | P08238 | 1/20 | 0.38 |
| ▸ | CA2 | P00918 | 1/20 | 0.35 |
| ▸ | CHKA | P35790 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.34 |
| ▸ | CES1 | P23141 | 1/20 | 0.33 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.33 |
| ▸ | DAGLA | Q9Y4D2 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.32 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.32 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.32 |
| ▸ | GRM1 | Q13255 | 1/20 | 0.32 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.32 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.31 |
| ▸ | LTA4H | P09960 | 1/20 | 0.30 |
| ▸ | FBP1 | P09467 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3712929 | 0.76 | CCR4 (0.38) | KDM4EHSD17B10LTA4HFBP1 | |
| SCHEMBL17859390 | 0.73 | CYP1A2 (0.34) | CYP1A2FBP1 | |
| SCHEMBL8488724 | 0.71 | TRPV4 (0.37) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL16632755 | 0.71 | CES1 (0.33) | CES1NCEH1DAGLAKDM4ECYP1A2 | |
| SCHEMBL31698519 | 0.71 | CES1 (0.33) | CES1NCEH1DAGLACYP1A2CYP2C9 | |
| SCHEMBL9911978 | 0.71 | PTGS2 (0.40) | HSP90AA1HSP90AB1CES1NCEH1DAGLA | |
| SCHEMBL5783345 | 0.69 | CES1 (0.47) | ALDH1A1CES1NCEH1DAGLAKDM4E | |
| SCHEMBL14602878 | 0.68 | IDH1 (0.32) | HSP90AA1HSP90AB1CES1NCEH1DAGLA | |
| SCHEMBL2901258 | 0.67 | LTA4H (0.53) | KDM4EKMT2ALTA4HFBP1 | |
| SCHEMBL13341092 | 0.67 | CYP3A4 (0.38) | HSP90AA1HSP90AB1CES1NCEH1DAGLA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 78 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8440711-B2 | 2-aryl-2-fluoropropanoic acids and derivatives and pharmaceutical compositions containing them | DOMPE PHA.R.MA S.P.A. (IT) | 2013-05-14 | — | — | US | claimed |
| EP-2094638-B1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE SPA (IT) | 2012-08-08 | — | — | EP | claimed |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE PHA.R.MA S.P.A. (IT) | 2010-03-25 | — | — | US | claimed |
| EP-2094638-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' pha.r.ma s.p.a. (IT) | 2009-09-02 | — | — | EP | claimed |
| WO-2008075184-A2 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | DOMPE' PHA.R.MA S.P.A. (IT) | 2008-06-26 | — | — | WO | claimed |
| US-7119113-B2 | Oxazoles as mGluR1 enhancers | HOFFMANN-LA ROCHE INC. (US) | 2006-10-10 | — | — | US | claimed |
| EP-1578746-B1 | OXAZOLES AS MGLUR1 ENHANCER | HOFFMANN LA ROCHE (CH) | 2006-06-14 | — | — | EP | claimed |
| EP-1578746-A1 | OXAZOLES AS MGLUR1 ENHANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2005-09-28 | — | — | EP | claimed |
| US-20040132792-A1 | Oxazoles as mGluR 1 enhancers | HOFFMANN-LA ROCHE INC. | 2004-07-08 | — | — | US | claimed |
| WO-2004056814-A1 | OXAZOLES AS MGLUR1 ENHANCER | F. HOFFMANN-LA ROCHE AG (CH) | 2004-07-08 | — | — | WO | claimed |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | MAZE THERAPEUTICS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-20250304576-A1 | IKK INHIBITORS | CANCER RESEARCH TECH LTD (GB) | 2025-10-02 | — | — | US | disclosed |
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | AGIOS PHARMACEUTICALS, INC. | 2025-08-21 | — | — | US | disclosed |
| WO-2025058986-A1 | SYSTEMS AND METHODS FOR AUTOMATED REACTION DEVELOPMENT | DEEPCURE INC. (US) | 2025-03-20 | — | — | WO | disclosed |
| EP-4522597-A1 | IKK INHIBITORS | Cancer Research Technology Limited (GB) | 2025-03-19 | — | — | EP | disclosed |
| EP-0763020-A1 | SUBSTITUTED PYRROLIDONE, THIAZOLIDONES OR OXAZOLIDONES AS HERBICIDES | ZENECA LIMITED (GB) | 1997-03-19 | — | — | EP | disclosed |
| EP-0749433-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1996-12-27 | — | — | EP | disclosed |
| WO-1996037466-A1 | PROCESS FOR THE PREPARATION OF (THIO-)CARBONIC/CARBAMIC ACID 2-PYRROLIDONYL-3-ESTERS, THIO ESTERS AND AMIDES | ZENECA LIMITED (GB) | 1996-11-28 | — | — | WO | disclosed |
| WO-1995033719-A1 | SUBSTITUTED PYRROLIDONE, THIAZOLIDONES OR OXAZOLIDONES AS HERBICIDES | ZENECA LIMITED (GB) | 1995-12-14 | — | — | WO | disclosed |
| WO-1995024403-A1 | (4,4-DIFLUOROBUT-3-ENYLTHIO)-SUBSTITUTED HETEROCYCLIC OR CARBOCYCLIC RING COMPOUNDS HAVING PESTICIDAL ACTIVITY | ZENECA LIMITED (GB) | 1995-09-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250262201-A1 | COMPOUNDS AND METHODS USEFUL FOR STABILIZING PHENYLALANINE HYDROXYLASE MUTATIONS | PAH, KDM8, PHF8 | HSP90AA1 2000/4885HSP90AB1 2515/4885CA2 1055/4885 |
| US-20250304576-A1 | IKK INHIBITORS | NFKBIA, IKBKE, IKBKB | HSP90AA1 2669/4885HSP90AB1 1964/4885CA2 3682/4885 |
| US-20040132792-A1 | Oxazoles as mGluR 1 enhancers | GRM1, GRM2, GRIN1 | HSP90AA1 2211/4885HSP90AB1 2313/4885CA2 1875/4885 |
| US-20100076034-A1 | 2-ARYL-2-FLUOROPROPANOIC ACIDS AND DERIVATIVES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM | FPR2, FPR3, FPR1 | HSP90AA1 3927/4885HSP90AB1 3579/4885CA2 1312/4885 |
| US-20250320196-A1 | APOL1 INHIBITORS AND METHODS OF USES THEREOF | APOL1, APOB, LDLR | HSP90AA1 4616/4885HSP90AB1 4025/4885CA2 4828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.